Investigational drug · Phase 2
CT7439
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CT7439"
First trial start
2024
Aug 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CT7439", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "CT7439" as an intervention, largest first.
Carrick Therapeutics LimitedIndustry
NCT06600789 · 50 participants (planned) · Start Aug 16, 2024 · Primary completion Mar 14, 2027
Drug: CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) · For: Solid Malignancies
Sites: Dallas, Texas; San Antonio, Texas; Fairfax, Virginia · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.
Pellarin I, Rossi V, Margiotta RG, et al. · Signal Transduct Target Ther 2026
- Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.
Watlington WK, Dayanidhi DL, Zokaasadi M, et al. · Mol Oncol 2026
- Therapeutic targeting of CDK12: a medicinal chemistry perspective.
Wang F, Dai H, Wan K, et al. · Bioorg Med Chem 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.